Leukemic phase of follicular lymphomas: an atypical presentation

References

• Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol 2010;28:2902–2913.
   PubMed Web of Science ®Google Scholar
• Harris NL, Nadler LM, Bhan AK. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities. Am J Pathol 1984;117:262–272.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504–1508.
   PubMed Web of Science ®Google Scholar
• Ferrer A, Salaverria I, Bosch F, et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007;109:2473–2480.
   PubMed Web of Science ®Google Scholar
• Chubachi A, Miura I, Hashimoto K, et al. High incidence of leukemic phase in follicular lymphoma in Akita, Japan: clinicopathologic, immunological and cytogenetic studies. Eur J Haematol 1993;50:103–109.
   PubMed Web of Science ®Google Scholar
• Ganguly S. Leukemic phase of follicular lymphoma after treatment with Etanercept in a patient with psoriasis. Am J Clin Dermatol 2009;10:125–126.
   PubMed Web of Science ®Google Scholar
• Hsieh YC, Lee LP, Chuang SS. Follicular lymphoma with many circulating buttock cells: a leukemic presentation mimicking mantle cell leukemia. Am J Hematol 2006;81:294–295.
   PubMed Web of Science ®Google Scholar
• Inaba T, Okamoto A, Tatsumi T, Fujita N, Shimazaki C. Hyperleukocytosis in patients with leukemic follicular lymphoma. Ann Hematol 2007;86:299–300.
   PubMed Web of Science ®Google Scholar
• Khokhar MT, Brito-Babapulle V, Matutes E, Catovsky D. Cytogenetic abnormalities in the leukemic phase of non-Hodgkin lymphoma. Cancer Genet Cytogenet 1995;83:18–24.
   PubMed Web of Science ®Google Scholar
• Mehta K, Pawel BR, Gadol C. Bone marrow necrosis in leukemic-phase follicular lymphoma. Arch Pathol Lab Med 1991;115:89–92.
   PubMed Web of Science ®Google Scholar
• Melo JV, Robinson DS, De Oliveira MP, et al. Morphology and immunology of circulating cells in leukaemic phase of follicular lymphoma. J Clin Pathol 1988;41:951–959.
   PubMed Web of Science ®Google Scholar
• Rymkiewicz G, Paszkiewicz-Kozik E, Blachnio K, et al. Unusual IgD+/CD38-follicular lymphoma with leukemic presentation. Med Oncol 2006;23:131–135.
   PubMed Web of Science ®Google Scholar
• Solé F, Woessner S, Florensa L, Perez-Losada A, Bonet C, Besses C. A new case of t(14;19)(q32;q13) in a patient with follicular lymphoma in leukemic phase. Cancer Genet Cytogenet 1994;75:72–73.
   PubMed Web of Science ®Google Scholar
• Agence Nationale d'Accréditation et d'Evaluation en Santé. Lecture critique de l'hémogramme: valeurs seuils à reconnaître comme probablement pathologiques et principales variations non pathologiques. Paris, FranceANAES1997.
   Google Scholar
• Manie E, Vincent-Salomon A, Lehmann-Che J, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009;69:663–671.
   PubMed Web of Science ®Google Scholar
• Come SE, Jaffe ES, Andersen JC, et al. Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations. Am J Med 1980;69:667–674.
   PubMed Web of Science ®Google Scholar
• O'Shea D, O'Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008;112:3126–3129.
   PubMed Web of Science ®Google Scholar
• Smith MD, Singleton TP, Balaraman S, et al. Case report: mantle cell lymphoma, prolymphocytoid variant, with leukostasis syndrome. Mod Pathol 2004;17:879–883.
   PubMed Web of Science ®Google Scholar
• Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology Am Soc Hematol Educ Program 2004:203–220.
   PubMedGoogle Scholar
• Al-Nawakil C, Tamburini J, Bardet V, et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma 2008;49:2012–2014.
   PubMed Web of Science ®Google Scholar